NovoCure Ltd. Files Q1 2025 10-Q Financial Report
Ticker: NVCR · Form: 10-Q · Filed: Apr 24, 2025 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 10-Q |
| Filed Date | Apr 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
NovoCure's Q1 2025 10-Q is in: financials updated, check balance sheet.
AI Summary
NovoCure Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and balance sheet information are presented, reflecting the company's financial position during this period.
Why It Matters
This report provides investors and stakeholders with a detailed look at NovoCure's financial health and operational status as of the end of the first quarter of 2025.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive medical device industry, facing significant research and development costs and market adoption challenges.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025 financial reporting)
- 1231 — Fiscal Year End (Indicates the company's annual reporting cycle)
Key Players & Entities
- NovoCure Ltd. (company) — Filer of the 10-Q report
- 20250331 (date) — Conformed period of report
- 20250424 (date) — Filed as of date
FAQ
What is the reporting period for this 10-Q filing?
The conformed period of report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filed?
This 10-Q was filed as of date 20250424.
What is NovoCure Ltd.'s fiscal year end?
NovoCure Ltd.'s fiscal year end is 1231.
What is the SEC file number for NovoCure Ltd.?
The SEC file number is 001-37565.
What is the SIC code for NovoCure Ltd.?
The Standard Industrial Classification (SIC) code is 3841, for Surgical & Medical Instruments & Apparatus.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 24, 2025 regarding NovoCure Ltd (NVCR).